Meta-Analysis of Efficacy and Safety of Proton Pump Inhibitors with Dual Antiplatelet Therapy for Coronary Artery Disease
Highlights
- • There is inconsistency in literature regarding use of proton pump inhibitors (PPI) with dual antiplatelet therapy (DAPT) in coronary artery disease (CAD).
- • In this meta-analysis, randomized controlled trials (RCTs) endorse the use of PPI with DAPT for prevention of gastrointestinal (GI) bleeding without compromising cardiovascular outcomes; whereas observational studies showed that PPI increased the risk of mortality and cardiovascular events without reducing GI bleeding.
- • Further RCTs are required to examine the use of PPI with DAPT in CAD.
Abstract
Background
There is inconsistency in the literature regarding the clinical effects of proton pump inhibitors (PPI) when added to dual antiplatelet therapy (DAPT) in subjects with coronary artery disease (CAD). We performed meta-analysis stratified by study design to explore these differences.